|
Join Our Premium Stock Market Digest
|
|
Taking center-stage in the biotech industry is oncology and endocrinology compound developer, Æterna Zentaris Inc. (NASDAQ: AEZS). On May 12th, 2010 the company announced the Food & Drug Administration (FDA) approved their “Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.”
In conjunction with broad interest among the investment community and members of TimelessWealth.net, a leading online investor and trader portal, we have published a technical opinion (technical analysis) on Æterna Zentaris Inc. (NASDAQ: AEZS).
We summarized our presentation with the following:
While one wave of short-term investors may be looking to exit, another is right around the corner and looking to capitalize on an upcoming catalyst in AEterna Zentaris' market. The following technical opinion on AEterna Zentaris, Inc. (NASDAQ: AEZS) outlines areas of support where traders may look to enter the 'play' and areas of resistance where sellers may pose a challenge for longs. Simple but effective market signals are also discussed in the following presentation.
Also of significant standing, Æterna Zentaris Inc. (NASDAQ: AEZS) is scheduled to “present a corporate overview at the upcoming Rodman & Renshaw Annual Global Investment Conference on Tuesday, May 18, 2010 at 9:00 a.m. (local time) in the Albemarie Suite of the Grosvenor House Hotel in London, U.K.”. This event may act as a price catalyst, should investors interpret that greater interest will be generated in the market as a result of a successful presentation.